High Risk Mutations in Critical Genes Do Not Significantly Affect Remission Rates and Minimal Residual Disease Clearance in Acute Myeloid Leukemia Patients Receiving CPX-351 Induction
Authors: Guolo Fabio , Riva Carola , Chies Maria , Vernarecci Chiara , Azzanelli Ylenia , Colombo Nicoletta , Rosellini Sara , Parodi Alessia , Tedone Elisabetta , Carminati Enrico , Puglisi Francesco , Nurra Clara , Fugazza Giuseppina , Cea Michele , Lemoli Roberto Massimo , Minetto Paola 
Published: December 2024

Background and aims

The better understanding of the molecular basis of Acute Myeloid Leukemia (AML) allowed to identify critical gene mutations related to a higher risk of treatment failure in patients receiving conventional 3+7 chemotherapy. Consequently, the presence of at least one mutation among TP53, ASXL1, BCOR, EZH2, SF3B1, SRSF2, STAG2, U2AF1, ZRSR2 confers adverse risk according to the recent European LeukemiaNet (ELN) 2022 classification.

In patients receiving less intensive treatment with hypomethylating agents plus Venetoclax (HMA+VEN), RUNX1, FLT3-ITD, N/KRAS, CBL, and KIT mutations have also been reported to predict treatment failure.

In the last years new drugs have been approved for the treatment of AML. CPX-351 showed superior efficacy if compared to conventional 3+7 in secondary AML (s-AML), and adverse risk mutations are particularly common in this context.

However, data concerning the prognostic relevance of adverse risk mutations in CPX-351 treated patients are lacking. Furthermore, a fraction of s-AML patients may be eligible to both CPX-351 and HMA-VEN induction, and there are no data about the efficacy of CPX-351 in s-AML patients with gene mutations predictive of HMA-VEN failure.

This study therefore aimed to explore the prognostic relevance of adverse risk mutations or mutational patterns linked to high risk of treatment failure with either conventional chemotherapy or with HMA-VEN in a cohort of elderly patients with s-AML treated with CPX-351.

Methods

The study involved 85 patients (median age 69, range 37-77) with s-AML or t-AML according to WHO 2016 classification, treated in our Center with CPX-351.

NGS was performed using the Myeloid Solution panel by SOPHiA Genetics, encompassing 34 critical genes mutations. Samples were processed on an Illumina MiSeq platform and analysis was performed with SOPHiA DDM® Software.

Minimal Residual Disease (MRD) was analysed in all patients achieving complete remission (CR) with multicolour flow-cytometry (MFC), with a threshold of 0.1%.

Results

Cytogenetic analysis showed high or intermediate risk karyotype in 48 (57%) and 37 patients (43%), respectively. Fifty-three patients (62%) showed high risk gene mutations, as defined by ELN 2022 risk score, and 64 patients (75%) displayed molecular aberrations predictive of resistance to HMA-VEN. Median number of gene mutations for single patient by NGS was 5 (range 2-10) and 45 patients had high mutational burden (≥ 4 mutations, 53%). Most frequent mutations were: CBL (79 %), CEBPA (59%), TET2 (41%), RUNX1 (39%), ASXL1 (29%), DNMT3A (29%), SRSF2 (29%), TP53 (26%). ELN 2022 risk score was favourable, intermediate or unfavourable in 3 (3%), 28 (33%) and 54 (64%) patients, respectively. After cycle 1, 66 patients (78%) achieved CR, with MFC-MRD negativity obtained in 48/66 responding patients (72%). Three patients (3.8%) died before response assessment, mainly due to infections.

Uni and multivariate analysis showed that both CR and MRD negativity rate were not affected by the ELN 2022 high-risk mutations or by any other gene mutation (p=n.s.). Furthermore, CR and MRD negativity were also unaffected by adverse cytogenetics or by the presence of high mutational burden or HMA-VEN resistance profile (p=n.s.).

After a median follow up of 42.1 months (CI 95%; 31-62 months), median OS was 19 months (CI 95% 15.89-20.69), whereas 2-year OS was 40.2%.

OS was not affected by any of the high-risk mutations, high mutational burden, or by the presence of HMA-VEN resistance profile (p=n.s.). Multivariate OS analysis showed that negative MRD was the strongest independent prognostic factor (p&lt;0.05).

In landmark analysis, patients achieving CR and proceeding to allogeneic stem cell transplantation consolidation (HSCT) (n=23) within 3 months from CR (n=8) had a significantly better outcome if compared to CR patients who did not receive HSCT (n=41) or proceeded to transplant later (n=15, p&lt;0.03).

Conclusions

CPX-351 is able to induce MRD negative CR in a large proportion of s-AML patients, with a lower impact from the presence of adverse risk features or HMA-VEN resistance profile. However, as the deep response achieved may be not durable, early HSCT consolidation is strongly advised in order to achieve long term survival.